Cramer's favorite stock of earnings season so far gets new props from analysts
Read more at CNBC
-
11 surprising things from this earnings season, including my favorite stock so far
Business - CNBC - Yesterday -
Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year
Business - CNBC - 4 days ago -
The Biggest Surprises of the N.B.A. Season So Far
Sports - The New York Times - 3 days ago -
Why Apple’s stock is a sweet play ahead of earnings, according to this analyst
Business - MarketWatch - October 14 -
Wall Street analysts get it wrong on two of our portfolio industrial stocks
Business - CNBC - October 21 -
Cramer's week ahead: Earnings from Boeing, Tesla, IBM and T-Mobile
Business - CNBC - October 18 -
Cramer’s week ahead: Earnings from Alphabet, Meta, Apple, Microsoft and Amazon
Business - CNBC - October 25 -
Jim Cramer wants to buy more shares of 2 portfolio companies with favorable catalysts
Business - CNBC - October 28 -
Cramer's week ahead: The election, Fed decision and earnings from Super Micro, Arm, Qualcomm and CVS
Business - CNBC - 3 days ago
More from CNBC
-
Palantir shares surge on rosy revenue outlook
Business - CNBC - 5 hours ago -
Trump's tariffs could trigger 'dramatic' price spikes on clothes, furniture, warns retail group
Business - CNBC - 2 hours ago -
As the election winds down, worries of 'bond vigilantes' and inflation hit markets
Business - CNBC - 7 hours ago -
What the stock market typically does after the U.S. election, according to history
Business - CNBC - 7 hours ago -
Judge rejects request to block Elon Musk $1 million voter giveaway
Business - CNBC - 3 hours ago
Latest in Business
-
Chinese equities outperform ahead of US election
Business - Financial Times - 58 minutes ago -
Trump's tariffs could trigger 'dramatic' price spikes on clothes, furniture, warns retail group
Business - CNBC - 2 hours ago -
Palantir’s stock surges as AI drives a further acceleration in growth
Business - MarketWatch - 2 hours ago -
Marqeta’s stock may shed a third of its value as these factors spur weak outlook
Business - MarketWatch - 2 hours ago -
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Business - MarketWatch - 2 hours ago